Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Обмен на изследователи2018–2023

ORBIS · Open Research Biopharmaceutical Internships Support

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2018-03-01 → 2023-08-31
Финансиране от ЕС
2 268 000 €
Участници
14
Схема
MSCA-RISE

Линиите свързват координатора с партньорите.

Накратко на български

Методите за синтез и дизайн на лекарствени форми се анализират, за да се подобрят техните биофармацевтични свойства. Това помага за намаляване на грешките в ранните изследвания и ускорява създаването на по-безопасни и ефективни медикаменти.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Open Research Biopharmaceutical Internships Support

Society needs a constant supply of new more effective medicines with decreased side effects. The current process of medicine development is cumbersome, lengthy, and often inefficient as only 1 in approximately 10,000 drug molecules will make it to the market. Studies demonstrated that the irreproducibility of preclinical research ranges from 51% to 89%, translating into over €25 billion wasted annually. Improvements could be achieved by advanced training programs to reinforce best practices related to core skills, technologies, and methods. Thus, the vision of the ORBIS network is to form a multidisciplinary transnational team that will establish improved competencies and characterization approaches for pharmaceutical research evaluating drug substances and dosage forms. The participants exchange skills and knowledge, which allow them to progress towards key advances in pharmaceutical sciences. They strengthen collaborative research between the different countries and sectors. The practical and economy-driven approach by industry is combined with scientific excellence to benefit European society with the implementation of scientific methods to solve practical problems and to inspire scientists to expand knowledge in line with industrial needs. A gap analysis has been performed and technological solutions are proposed by the team to improve the processes of drug synthesis, preformulation, dosage form design, and biopharmaceutical properties. This supports Europe’s aspiration to become a global leader in providing innovative, efficient, safe, patient-friendly, and affordable medicinal products. To achieve this, we planned collaborative, complementary, and industrial application-driven research, leading to a substantial and sustainable improvement of the medicine development process. The educational mission of the project is to enhance the skills and expertise of staff involved in academic and industrial pharmaceutical R&D activities, especially early-stage researchers. The project is increasing their employability and the overall competence of the sector. Knowledge exchange underpins the following major activities: research & commercialisation, teaching & learning as well as knowledge dissemination to the wider community. Due to the diversity of the group and multiplicity of geographic locations, a number of tools and approaches is used for knowledge sharing within the team. Summer Schools are executed on an annual basis (four in total) for all participants and responsibility for organising the events is circulated. Annual workshops as smaller events support collaboration within the project.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The current process of drug development is lengthy and inefficient. Only 1 out of approximately 10,000 drug molecules enters the market. Therefore more effective medicines, demanded by society, cannot be provided by pharmaceutical industry. To fill this gap, Open Research Biopharmaceutical Internships Support (ORBIS) proposes that the high attrition rate of new drug candidates might be reduced by over 20% by improving early stage R&D productivity. The overarching objective of ORBIS is therefore to form an international and inter-sectoral academic and industrial network. The action is aimed at improving the preclinical pathway of medicine development concentrating on processes and technologies. The goal is to integrate multidisciplinary research by involving academia and industry from EU (Poland, Ireland, Finland, Germany and Czech Republic), EU associated country (Ukraine) and US to address the poor drug bioavailability as 70% of actives have solubility and/or membrane permeability problems. The action is addressed at selected molecules of class II and IV of Biopharmaceutics Classification System, to improve their pharmaceutical potential. The complementary consortium comprises experts in computations, physical chemistry, material science, nanotechnology, pharmacy, pharmacology and bioanalysis. The secondments will create a stimulating environment for early stage researchers to advance their individual career and soft skills. EU scientists will amalgamate their expertise in drug synthesis and dissolution, oral formulations, and bioanalytical methods with the knowledge on dermal research provided by the US partner. ORBIS will consolidate the existing links, promote long-term cooperation and exchange of knowledge between beneficiaries and partners. ORBIS will also enhance dissemination of new research outcomes and raise the awareness among the general public of the importance of drug delivery research that makes new drugs more accessible and affordable for society.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз